Researchers Investigate High Rates of MDR- and Rifampicin-Resistant TB Among Re-Treatment Cases

Globally, 3.9 percent of new and 21 percent of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study by Ragonnet, et al. (2017) aims to assess the respective contributions of the different causal pathways leading to MDR/RR-TB at re-treatment.

The researchers used a simple mathematical model to simulate progression between the different stages of disease and treatment for patients diagnosed with TB. The model is parameterised using region and country-specific TB disease burden data reported by the World Health Organization (WHO). The contributions of four separate causal pathways to MDR/RR-TB among re-treatment cases are estimated: I) initial drug-susceptible TB with resistance amplification during treatment; II) initial MDR/RR-TB inappropriately treated as drug-susceptible TB; III) MDR/RR-TB relapse despite appropriate treatment; and IV) re-infection with MDR/RR-TB.

At the global level, Pathways I, II, III and IV contribute 38% (28–49, 95% Simulation Interval), 44% (36–52, 95% SI), 6% (5–7, 95% SI) and 12% (7–19, 95% SI) respectively to the burden of MDR/RR-TB among re–treatment cases. Pathway II is dominant in the Western Pacific (74%; 67–80 95% SI), Eastern Mediterranean (68%; 60–74 95% SI) and European (53%; 48–59 95% SI) regions, while Pathway I makes the greatest contribution in the American (53%; 40–66 95% SI), African (43%; 28–61 95% SI) and South-East Asian (50%; 40–59 95% SI) regions.

The researchers concluded that failure to diagnose MDR/RR-TB at first presentation is the leading cause of the high proportion of MDR/RR-TB among re-treatment cases. These findings highlight the need for contextualized solutions to limit the impact and spread of MDR/RR-TB.

Reference: Ragonnet R, et al. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infectious Diseases. 2017;17:36

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish